China’s CoronaVac safe for use in children: study
The Hindu
Higher dose induced neutralising antibody responses in trials of 3-17 year-olds
A higher dose of the Chinese vaccine CoronaVac was “well tolerated and safe, and induced neutralising antibody responses in children and adolescents aged 3-17 years”, a study in the recent edition of the peer-reviewed journal Lancet Infectious Diseases has stated. The seroconversion rates of neutralising antibodies in children and adolescents with two different doses were over 96% after a double-dose vaccination, the paper reported. The double-blind randomised, controlled, phase 1/2 clinical trial of CoronaVac (inactivated SARS-CoV-2), in healthy children and adolescents aged 3-17 years was conducted at the Hebei Provincial Center for Disease Control and Prevention in Zanhuang (Hebei, China).More Related News

Former CM B.S. Yediyurappa had challenged the first information report registered on March 14, 2024, on the alleged incident that occurred on February 2, 2024, the chargesheet filed by the Criminal Investigation Department (CID), and the February 28, 2025, order of taking cognisance of offences afresh by the trial court.